“…The ability of neuraminidase/sialidase inhibitors siastatin B (Kudo et al, 1993; Tailford et al, 2015), N‐acetyl‐2,3‐dehydro‐2‐deoxyneuraminic acid (Magesh et al, 2008), Fv32r (previously also synthesized as 4‐amino‐DANA (Smith et al, 2001)), and the zanamivir precursor zanamivir amine (Caceres et al, 2022) to inhibit Cj0843c suggests that such inhibitors could be starting points for design of more‐potent LT inhibitors. Zanamivir is FDA‐approved to treat flu, and many sialidase inhibitor analogs have previously been synthesized (Keil et al, 2022; Laborda et al, 2016), which could be tested for their ability to inhibit LTs.…”